XGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Exagen Inc (XGN) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite moderate revenue growth and positive analyst sentiment, the stock faces significant near-term challenges, including bearish technical indicators, declining gross margins, and muted ASP growth. With no strong trading signals or recent positive catalysts, it is advisable to hold off on investing until clearer signs of recovery or growth emerge.
The technical indicators for XGN are bearish. The stock's moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downtrend, and the RSI of 34.492 is neutral but leaning toward oversold territory. The MACD is slightly positive but not strongly bullish. The stock is trading near its key support level of 2.717, with resistance at 3.205, suggesting limited upside potential in the short term.
The company's Q4 2025 revenue increased by 21.79% YoY, and analysts maintain a Buy rating despite lowering price targets. Management's strong reimbursement background and potential ASP upside in FY26 and FY27 are also positive long-term factors.
Gross margin dropped by 10.84% YoY in Q4 2025, and ASP headwinds persist due to a large direct bill client converting to commercial billing. Analysts have consistently lowered price targets, and the stock has experienced a 60% drop following Q3 results. No recent news or significant insider/hedge fund activity suggests a lack of immediate positive momentum.
In Q4 2025, revenue grew by 21.79% YoY to $16.63M, and net income improved by 24.25% YoY to -$4.67M. However, gross margin declined to 55.35%, down 10.84% YoY, and EPS remained flat at -0.2. While revenue growth is promising, declining margins and persistent losses are concerning.
Analysts maintain a generally positive outlook with Buy ratings, but price targets have been consistently lowered, reflecting near-term challenges. The average target has dropped to $10, down from $12-$18 earlier this year, citing ASP and gross margin pressures. Analysts expect double-digit revenue growth to resume in 2027, but near-term growth remains muted.
